The World's Only Transdermal Dopamin Agonist, Neupro® Patch, Approved in Japan for Both Parkinson's Disease and Restless Legs Syndrome The only transdermal dopamine agonist*1 system, which helps ...

Latest safety and efficacy results for rotigotine in the treatment of moderate to severe restless legs syndrome presented at major North American neurology congress Brussels (Belgium), 13 April 2010, ...

UCB will need to resolve issues concerning crystal formation before regulators in the USA approve the Belgian firm’s Neupro patch for Parkinson’s disease and restless legs syndrome. UCB will need to ...

Rotigotine 2 mg/24 hours, 4 mg/24 hours, 6 mg/24 hours; transdermal patch; contains sulfites. Neupro is a transdermal patch containing rotigotine, a D3/D2/D1 dopamine agonist. The mechanism of action ...

Neupro (rotigotine transdermal system, from UCB and Schwarz Pharma) patches are being recalled due to the formation of rotigotine crystals in the patches. When the drug crystallizes, less drug is ...

A new treatment for Parkinson's disease, in the form of a patch, promises an end to "off time" - that period between doses when tremors return It is the first time treatment for Parkinson's has come ...

Atlanta, April 14th, 2010 – Evidence of Neupro® (Rotigotine Transdermal System) improving motor as well as non-motor symptoms of Parkinson's disease was presented at the 62nd American Academy of ...

ATLANTA — UCB has launched a new drug for treating Parkinson's disease and restless legs syndrome, the company said Monday. The Belgian drug maker announced the launch of Neupro (rotigotine) ...

UCB has already made progress in reformulation and remains committed to bringing Neupro® to U.S. patients suffering from Parkinson's disease and Restless Leg Syndrome Brussels (Belgium) - April 23, ...

Atlanta, April 13th, 2010 – New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome (RLS) ...